Circulating influenza viruses and the effectiveness of seasonal influenza vaccine in Romania, season 2012-2013 / Virusurile gripale circulante și eficacitatea vaccinului gripal sezonier în România, în sezonul 2012-2013

Open access


Backgound. Using influenza epidemiological and virological surveillance data, we aimed at investigating the profile of influenza viruses circulating in Romania during the season 2012-2013 and estimating the effectiveness (VE) of the seasonal vaccine. Methods. We tested all specimens collected from patients with influenza like illness (ILI) in the national surveillance system between week 40/2012 to week 20/2013. Influenza A/B positive specimens identified by molecular detection (RT-PCR) were further characterized. We used hemagglutination inhibition assay for antigenic characterization and chemiluminiscence assay for the antiviral susceptibility testing. Subsequently we conducted nucleotide sequencing of hemagglutinin and neuraminidase genes and phylogenetic tree analyses. We estimated influenza VE using the test negative case-control study design, as 1-odds ratio of vaccination among ILI cases positive for influenza and ILI negative controls. Results and Discussions. We tested 1087 specimens, and 537 cases were positive (56.2% influenza B, 40.6% A(H1N1)pdm09, 3.2% A(H3N2). Sixty-four influenza viruses were antigenically and/or genetically characterized. A(H1N1)pdm09 viruses were related to the vaccine strain A/ California/07/2009 and clustered with genetic group 6 similar to A/St. Petersburg/27/2011. Influenza B viruses belonged to clade 2 of type B/Yamagata lineage, related to B/Estonia/55669/2011 except one, B/Victoria lineage, representative strain B/Brisbane/60/2008. A(H3) viruses clustered with group 3C of the A/Victoria/208/2009 clade, similar to the vaccine strain A/Victoria/361/2011. All tested strains (57) demonstrated susceptibility to oseltamivir and zanamivir. The adjusted seasonal influenza vaccine effectiveness against influenza A(H1N1)pdm09 (N=119) was 76.9% (95% CI: -113.4, 98.5), suggesting a good protection, consistent with the good match between the vaccine and circulating strains.

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003 Nov 22;362(9397):1733-45. DOI: 10.1016/ S0140-6736(03)14854-4

2. Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1861-70. DOI: 10.1098/rstb.2001.0999

3. World Health Organization. Influenza. Wkly Epidemiol Rec. 1978;53:21-4.

4. Nakajima K, Desselberger U, Palese P. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature. 1978;274:334-9. DOI: 10.1038/274334a0

5. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun 18;360(25):2605-15. DOI: 10.1056/NEJMoa0903810

6. Kanegae Y, Sugita S, Endo A, Ishida M, Senya S, Osako K, et al. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol. 1990;64:2860-5.

7. Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 1992;73:2737-42. DOI: 10.1099/0022-1317-73-10-2737

8. National Institute of Public Health, Romania. Influenza, ARI and SARI surveillance methodology, 2012-2013. [Metodologia de supraveghere a gripei, infectiilor respiratorii acute si SARI pentru sezonul 2012-2013]. Available on: (accessed on 7/01/2014).

9. Valenciano M, Ciancio Bc, I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill. 2012;17(39):11-21.

10. European Centre for Disease Prevention and Control (ECDC), Protocol for case-control studies to measure pandemic and seasonal influenza vaccine effectiveness in the European Union and European Economic Area Member States, Technical document. Available from:

11. European Commission. Commission Decision 2009/363/EC of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council, OJ L 110, 1.5.208, p. 58. Available on line:

12. Biere B, Bauer B, Schweiger B. Differentiation of Influenza B Virus Lineages Yamagata and Victoria by Real-Time PCR. J Clin Microbiol. 2010;48 (4):1425-7. DOI: 10.1128/JCM.02116-09

13. World Health Organization. Indentification of the haemagglutinin subtype of viral isolates by haemagglutination inhibition testing. Manual for the laboratory diagnosis and virological surveillance of influenza, WHO Press. Geneva. 2011;43-59.

14. Necula G, Mihai ME, Sbarcea CE, Dinu S, Lupulescu E, Ceausu E, et al. Overview of influenza virus antiviral resistance in Romania in the last four epidemic seasons - phenotyping, genotyping and molecular analysis study. Rev Romana Med Lab. 2011;19(3):227-40.

15. Pitigoi D, Lupulescu E, Alexandrescu V, Baetel AE, Sbarcea C, Ionita E, et al. The effectiveness of seasonal influenza vaccine in persons older than 65 years in Romania. Case-control pilot study I-MOVE, 2008-2009, [Eficacitatea vaccinului gripal sezonier la persoanele cu varsta peste 65 de ani din Romania. Studiul pilot caz-martor I-MOVE, 2008-2009]. Bacteriol Virusol Parazitol Epidemiol. 2009 aprilie-iun;54(2):59-67.

16. Pitigoi D, Ivanciuc AE, Necula G, Lupulescu E, Alexandrescu V, Savulescu C. Influenza vaccine effectiveness to prevent medically attended laboratory confirmed influenza during season 2010-2011 in Romania: a case control study. Rev Romana Med Lab. 2012;20(2):127-34.

17. World Health Organization Influenza Centre London. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2014, 23rd - 25th September 2013.

18. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Geneva World Health Organisation on 7/01/2014).

19. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility. Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74.

20. Pistol A, Popescu R. ARI and ILI surveillance in Romania, week 40/2012-week 20/2013 [Supravegherea infectiilor respiratorii acute si a gripei in Romania, S 40/2012-S20/2013]. Available at: (accessed on 7/01/2014).

21. European Centre for Disease Prevention and Control (ECDC). Weekly influenza surveillance overview, April 2013.

22. World Health Organization. Summary of the 2012-2013 influenza season in the WHO European Region. 2013

23. Rykkvin R, Kilander A, Dudman SG, Hungnes O. Within- patient emergence of the influenza A(H1N1)pdm09 HA1 222G variant and clear association with severe disease, Norway. Euro Surveill. 2013 Jan 17;18(3). pii: 20369.

24. Public Health England. Surveillance of influenza and other respiratory viruses, including novel respiratory viruses, in the United Kingdom: Winter 2012/13. Available at: (accessed on 7 January 2014).

25. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6):pii=20701.

26. Savulescu C, Valenciano M, de Mateo S, Larrauri A; cycEVA Study Team. Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network--pilot case-control studies using different control groups, 2008-2009 season, Spain. Vaccine. 2010;28(16):2903-7. DOI: 10.1016/j.vaccine.2010.01.054

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 151 151 16
PDF Downloads 62 62 7